New drug hope for women with Tough-to-Treat uterine cancer
NCT ID NCT02491099
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 42 times
Summary
This phase 2 trial tests the drug afatinib in 50 women with a rare, aggressive uterine cancer that has come back or not responded to treatment. The cancer must have a specific marker called HER2. Afatinib is a pill taken daily that targets HER2 to try to stop the cancer from growing. The main goal is to see if the drug can keep the cancer from getting worse for at least 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2/NEU+ UTERINE SEROUS CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
COMPLETEDBoston, Massachusetts, 02114, United States
-
University of Arizona Cancer Center
COMPLETEDTucson, Arizona, 85724, United States
-
Yale New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Afatinib
What this could lead to
If successful, this could provide a new treatment option to slow or shrink HER2-positive uterine serous carcinoma that has returned or not responded to prior therapy.
What could go wrong
This is a small, early-phase trial with only 50 participants, so results may not apply broadly. Afatinib can cause side effects like diarrhea and rash, and the cancer may still progress.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.